Home / Intelligence / Case Studies / Biosimilar Differentiation Strategy
Trinity developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada, and select LatAm and MEA countries.
Geographic Scope: 
Client Situation:
The client wanted to identify the service offerings and contracting that can drive differentiation and preference of a biosimilar versus the originator biologic and other biosimilars.
Trinity’s Solution
Trinity conducted an internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185 stakeholders, including key opinion leaders (KOLs), physicians, nurses, hospital administrators and payers.
Deliverables
- Catalogue of value-added services and contracts offered by the originator biologic across market segments
- Biosimilar defense strategies implemented by the manufacturer of the originator biologic
- Stakeholder influence map outlining formal and informal leverage points to drive biosimilar uptake
- Service offering and contracting expectations for biosimilars and impact on biosimilar differentiation
- Strategic recommendations to drive differentiation of a biosimilar
Project Outcomes & Impact
Trinity was able to support the client with driving differentiation of a biosimilar through service offerings and contracting, with strategies tailored to market segment.
Related Intelligence
Webinars
Most-Favored Nation Pricing Policy: Why One Size Doesn’t Fit All
September 25, 2025 | 1:00 – 2:00 PM ET
As U.S. leaders promote a drug pricing vision based on Most-Favored Nation (MFN) principles, ensuring that U.S. consumers have access to the best available prices among advanced nations, pharmaceutical companies are facing increased uncertainty and are evaluating strategic options. This session will bring together Trinity experts to discuss how this initiative could realistically lead to […]
Sign Up Now
Blog
A Shrinking Safety Net: OBBBA’s Ripple Effects on the Pharma Industry
President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade. Central to the legislation is the estimated loss of insurance coverage for 16 million people[2], fundamentally reshaping access to care for […]
Read More
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
Available On Demand
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Watch Now